Journal
INFLAMMATION RESEARCH
Volume 72, Issue 4, Pages 683-701Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00011-023-01700-8
Keywords
Antiseizure drug (ASD); Biomarker; Chemokine; Cyclooxygenase 2 (COX-2); Cytokine; EP2; Epileptogenesis; High mobility group box 1 (HMGB1); Microsomal prostaglandin E synthase-1 (mPGES-1); Neuroinflammation; Prostaglandin E2 (PGE(2)); Seizure; Status epilepticus (SE)
Categories
Ask authors/readers for more resources
Epilepsy is a chronic neurological disorder characterized by spontaneous seizures and behavioral comorbidities. Acquired epilepsy, which is associated with prior neurological insults, is believed to be partially caused by inflammation within the brain. Neuroinflammatory processes such as microglial and astrocytic activation, production of pro-inflammatory molecules, blood-brain barrier breakdown, and upregulation of inflammatory signaling pathways have been observed after seizure-precipitating events. Understanding these inflammatory processes may lead to the development of new therapeutic targets and biomarkers for acquired epilepsy.
Epilepsy is a group of chronic neurological disorders that have diverse etiologies but are commonly characterized by spontaneous seizures and behavioral comorbidities. Although the mechanisms underlying the epileptic seizures mostly remain poorly understood and the causes often can be idiopathic, a considerable portion of cases are known as acquired epilepsy. This form of epilepsy is typically associated with prior neurological insults, which lead to the initiation and progression of epileptogenesis, eventually resulting in unprovoked seizures. A convergence of evidence in the past two decades suggests that inflammation within the brain may be a major contributing factor to acquired epileptogenesis. As evidenced in mounting preclinical and human studies, neuroinflammatory processes, such as activation and proliferation of microglia and astrocytes, elevated production of pro-inflammatory cytokines and chemokines, blood-brain barrier breakdown, and upregulation of inflammatory signaling pathways, are commonly observed after seizure-precipitating events. An increased knowledge of these neuroinflammatory processes in the epileptic brain has led to a growing list of inflammatory mediators that can be leveraged as potential targets for new therapies of epilepsy and/or biomarkers that may provide valued information for the diagnosis and prognosis of the otherwise unpredictable seizures. In this review, we mainly focus on the most recent progress in understanding the roles of these inflammatory molecules in acquired epilepsy and highlight the emerging evidence supporting their candidacy as novel molecular targets for new pharmacotherapies of acquired epilepsy and the associated behavioral deficits.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available